Increased survival in metastatic NSCLC patients on immunochemotherapy seen in trials
A KEYNOTE on PD-L1 as a predictive biomarker of immunotherapy response: a complex picture
Fred Hirsch • 11 Apr 2018
A new standard of care for advanced lung cancer: what’s next for pembrolizumab?
Martin Reck • 11 Apr 2018